Pauci-immune renal vasculitis: Natural history, prognostic factors, and impact of therapy

Jennette, 1997, Small-vessel vasculitis, N Engl J Med, 337, 1512, 10.1056/NEJM199711203372106 Zeek, 1953, Periarteritis nodosa and other forms of necrotizing angiitis, N Engl J Med, 248, 764, 10.1056/NEJM195304302481805 Hunder, 1990, The American College of Rheumatology 1990 criteria for the classification of vasculitis, Arthritis Rheum, 33, 1065, 10.1002/art.1780330802 Rao, 1998, Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis, Ann Intern Med, 129, 345, 10.7326/0003-4819-129-5-199809010-00001 Jennette, 1994, Nomenclature of systemic vasculitides. Proposal of an International Consensus Conference, Arthritis Rheum, 37, 187, 10.1002/art.1780370206 Westman, 1998, Relapse rate, renal survival, and cancer morbidity in patients with Wegener’s granulomatosis or microscopic polyangiitis with renal involvement, J Am Soc Nephrol, 9, 842, 10.1681/ASN.V95842 Guillevin, 1999, Microscopic polyangiitis. Clinical and laboratory findings in eighty-five patients, Arthritis Rheum, 42, 421, 10.1002/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6 Hogan, 1996, Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis, J Am Soc Nephrol, 7, 23, 10.1681/ASN.V7123 Gans, 1993, Clinical features and outcome in patients with glomerulonephritis and antineutrophil cytoplasmic autoantibodies, Nephron, 64, 182, 10.1159/000187311 Falk, 1990, Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis, Ann Intern Med, 113, 656, 10.7326/0003-4819-113-9-656 Geffriaud-Ricouard, 1993, Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients, Clin Nephrol, 39, 125 Pettersson, 1995, Incidence and outcome of pauci-immune necrotizing and crescentic glomerulonephritis in adults, Clin Nephrol, 43, 141 Hosmer, 1989 Norusis, 1994 Urowitz, 1976, The bimodal mortality pattern of systemic lupus erythematosus, Am J Med, 60, 221, 10.1016/0002-9343(76)90431-9 Falk, 1997, ANCA small-vessel vasculitis, J Am Soc Nephrol, 8, 314, 10.1681/ASN.V82314 Adler, 1996, Secondary glomerular diseases, 1498 Couser, 1988, Rapidly progressive glomerulonephritis: Classification, pathogenetic mechanisms, and therapy, Am J Kidney Dis, 9, 449, 10.1016/S0272-6386(88)80079-9 Bolton, 1989, Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis, Am J Nephrol, 9, 368, 10.1159/000167998 Angangco, 1994, Does truly ‘idiopathic’ crescentic glomerulonephritis exist?, Nephrol Dial Transplant, 9, 630, 10.1093/ndt/9.6.630 Bindi, 1993, Necrotizing crescentic glomerulonephritis without significant immune deposits: A clinical and serological study, Q J Med, 86, 55 Ferrario, 1994, Critical re-evaluation of 41 cases of “idiopathic” crescentic glomerulonephritis, Clin Nephrol, 41, 1 Davies, 1982, Segmental necrotizing glomerulonephritis with antineutrophil antibody: Possible arbovirus aetiology?, BMJ, 285, 606, 10.1136/bmj.285.6342.606 Hall, 1984, Vasculitis and glomerulonephritis: A subgroup with an anti-neutrophil cytoplasmic antibody, Aust N Z J Med, 14, 277, 10.1111/j.1445-5994.1984.tb03769.x Gross, 1993, ANCA and associated diseases: Immunodiagnostic and pathogenetic aspects, Clin Exp Immunol, 91, 1, 10.1111/j.1365-2249.1993.tb03345.x Jennette, 1993, Pathogenic potential of anti-neutrophil cytoplasmic antibodies, 7 Stegeman, 1996, Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis, N Engl J Med, 335, 16, 10.1056/NEJM199607043350103 DeOliviera, 1995, Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis, Am J Kidney Dis, 25, 380, 10.1016/0272-6386(95)90098-5 Gaskin, 1995, Prevention of relapse in systemic vasculitis, J Am Soc Nephrol, 6, 921A Glassock, 1996, Primary glomerular diseases, 1392 Guillevin, 1997, A prospective, multicentre, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis, Arthritis Rheum, 40, 2187, 10.1002/art.1780401213 Haubitz, 1998, Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement. A prospective, randomized study, Arthritis Rheum, 41, 1835, 10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q Maschio, 1996, Effect of the angiotensin-converting-enzyme inhibitor benazApril on the progression of chronic renal insufficiency, N Engl J Med, 334, 939, 10.1056/NEJM199604113341502 The GISEN Group, 1997, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group, Lancet, 349, 1857, 10.1016/S0140-6736(96)11445-8 Peterson, 1995, Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study, Ann Intern Med, 123, 754, 10.7326/0003-4819-123-10-199511150-00003 Brazy, 1990, Progressive renal disease: Role of race and antihypertensive medications, Kidney Int, 37, 1113, 10.1038/ki.1990.93 Savige, 2000, Antineutrophil cytoplasmic antibodies and associated diseases: A review of the clinical and laboratory features, Kidney Int, 57, 846, 10.1046/j.1523-1755.2000.057003846.x